Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04585841
Recruitment Status : Not yet recruiting
First Posted : October 14, 2020
Last Update Posted : October 22, 2020
Sponsor:
Collaborator:
Zealand University Hospital
Information provided by (Responsible Party):
Jens Rikardt Andersen, University of Copenhagen

Brief Summary:
An intervention study on the effect of cannabidiol on lean body mass in cancer patients receiving chemotherapy, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark. Fat free mass will be measured by bioimpedance spectroscopy. As secondary outcomes protein and energy intake, nausea, taste alterations and life quality will be assessed by oral interviews and questionnaires.

Condition or disease Intervention/treatment Phase
Lean Body Mass Cannabis Cancer Nausea Cachexia Emesis Appetitive Behavior Drug: Cannabidiol Phase 1

Detailed Description:

One of the side effects of chemotherapy is loss of lean body mass. With a non-blinded two armed intervention design this study will examine the effect of cannabidiol on fat free mass in cancer patients. The study will include patients who are diagnosed with cancer and scheduled to undergo at least 4 courses of paclitaxel or oxaliplatin based chemotherapy.

The hypothesis is that patients receiving cannabidiol (300mg/day) will have no change in lean body mass at the end of the study. In extension to this, we hypothesize that cannabidiol will increase the energy and protein intake because of increased appetite and decreased nausea and emesis.

Recruitment and data collection will take place at the department of Clinical Oncology at Zealand University Hospital, Roskilde.

Each patient will be included for four courses of paclitaxel or oxaliplatin based chemotherapy. The length between each chemotherapy course is three weeks.

Lean body mass will be measured by impedance spectroscopy before every chemotherapy treatment.

For two and a half months, patients will answer a weekly questionnaire about nausea, appetite and quality of life in general. The questionnaire is developed for this study.

In addition to the questionnaire, the patients will be interviewed about their daily dietary intake to quantify their energy and protein intake, calculated as percentage of estimated need.

Another side effect of chemotherapy is alterations in taste. In this study, we will examine the patient's taste in sweet and salty. At the day of chemotherapy, the patients will have a taste test. In the taste test the patients must tell which of the basic flavors they presume they are consuming, as well as how strong the taste is , on a scale from 1 to 10.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Cancer patients entering a phase 2 trial on cannabis for prevention on chemotherapy-induced peripheral neuropathy are asked to enter this study monitoring cannabidiols effect on lean body mass during chemotherapy. 40 participants are expected to enter intervention group, 20 participants in control group.
Masking: None (Open Label)
Masking Description: Control group will enter this study if not wanting to participate in cannabidiol study. Due to this masking is not possible.
Primary Purpose: Supportive Care
Official Title: The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy
Estimated Study Start Date : November 1, 2020
Estimated Primary Completion Date : March 30, 2021
Estimated Study Completion Date : June 30, 2021

Arm Intervention/treatment
Experimental: Intervention group
Cancer patients receiving cannabidiol
Drug: Cannabidiol
Patients will receive cannabidiol in the period of time they receive chemotherapy.
Other Name: No intervention

No Intervention: Control group
Cancer patients not receiving cannabidiol



Primary Outcome Measures :
  1. Number of patients with change in lean body mass from baseline. [ Time Frame: 10 weeks ]
    Changes in lean body mass measured at baseline and before each chemotherapy treatment (scheduled for every three weeks) measured in kg by bioimpedance. Changes are assessed as change in percentage of total lean body mass weight.


Secondary Outcome Measures :
  1. Change in food intake [ Time Frame: 10 weeks ]

    Change in food intake from baseline measured in kilojoule (kJ). Changes in intake of protein- and energy assessed by weekly nutritional recall interviews of weekly intake.

    Change in food intake from baseline measured in kJ. Changes in intake of protein- and energy assessed by weekly nutritional recall interviews of weekly intake.


  2. Change in energy intake . [ Time Frame: 10 weeks ]

    Change in intake of energy assessed by weekly nutritional 24-hour recall interview.

    Assessment of energy requirement using Harris Benedict- formula estimated from height in cm, weight in kilo, age in years and physical activity level (PAL). Height and weight is derived from bioimpedance measurements in Outcome 1. Age is derived from conversation with the participant. PAL is assessed after conversation with the participant. Energy requirements will be reported as kilojoule (Kj).

    Correlation between relative fulfilment of energy requirement, and change therein. Energy requirement is estimated by Harris-Benedict formula, including among other assessment of physical activity level.


  3. Change in protein intake [ Time Frame: 10 weeks ]
    Change in protein intake from baseline measured in kJ Protein requirement is estimated from the Danish Health Authority´s recommendation for adult patients. Protein intake is assessed by 24-hour recall of nutrition intake.

  4. Change in nausea [ Time Frame: 10 weeks ]

    Changes in nausea from baseline is assessed by a categorical scale in a weekly questionnaire if the participant is experiencing nausea: daily, five or six times a week, three or four times a week, one or two times a week, not at all. "Not at all" being the lowest score, "Daily" being the highest.

    The Questionnaire is written in danish and is called Livskvalitet (Quality of life) and the scale is for the question "Symptomer" (symptoms). The questionnaire is developed for this study and language validation has been done with 12 patients from the same department as the study will take place


  5. Change in emesis [ Time Frame: 10 weeks ]

    Changes in emesis from baseline is assessed by a categorical scale in a weekly questionnaire if the participant is experiencing nausea: daily, five or six times a week, three or four times a week, one or two times a week, not at all. "Not at all" being the lowest score, "Daily" being the highest.

    The Questionnaire is written in danish and is called Livskvalitet (Quality of life) and the scale is for the question "Symptomer" (symptoms). The questionnaire is developed for this study and language validation has been done with 12 patients from the same department as the study will take place.


  6. Difference in taste during chemotherapy. [ Time Frame: 10 weeks ]
    Difference in taste from baseline is measured by a sensory test with flavour neutral mashed potato added sweet, sour or umami flavour in two strengths of flavour. Participants will answer which flavour they taste and how strong the flavour is on a scale from 1-10. Also the patients preference in the three flavours will be monitored.

  7. Change in appetite [ Time Frame: 10 weeks ]
    Changes in appetite from baseline is assessed by a categorical scale in a weekly questionnaire about the patient's subjective estimation on portion size: bigger, the same or smaller than usual compared to the weekly nutritional 24-hour recall interview. Bigger being the highest value, smaller than usual being the lowest value.

  8. Change in Quality of life (QOL) [ Time Frame: 10 weeks ]

    To estimate the patient' QOL from baseline by a weekly questionnaire about the patient's well being. It will be compared with the questions about appetite, taste, nausea and emesis. It will also be compared with the patient medical record.

    The Questionnaire is written in danish and is called Livskvalitet (Quality of life) and the scale is for the question "Symptomer" (symptoms). The questionnaire is developed for this study and language validation has been done with 12 patients from the same department as the study will take place




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A diagnosis of cancer
  • Fulfill criteria for starting chemotherapy
  • Must be able to stand upright
  • Have the possibility of contact by telephone
  • No previous treatment with taxanes or platinums
  • Scheduled to undergo lest 4 courses of paclitaxel or 4 courses of oxaliplatin based chemotherapy
  • If female and fertile, must have been menopausal for 1 year or negative pregnancy test at inclusion and use approved contraceptive measures

Exclusion Criteria:

  • Pregnant
  • Breastfeeding
  • Unable to complete patient reported outcomes (PRO)-measurements
  • Previously received taxanes or platinum-based chemotherapy
  • Use of cannabinoids. If in use, treatment must be stopped 4 days prior to inclusion
  • If using any anti epileptic or antidepressant medicine. Treatment must be stable (no changes in dosing in last 30 days) prior to inclusion. However, any treatment with Clobazam is not allowed due to major interaction with cannabidiol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04585841


Contacts
Layout table for location contacts
Contact: Jens Rikardt Andersen, MD +4535332504 jra@nexs.ku.dk
Contact: Simone D Hasselsteen +4528140880 dyring_@hotmail.com

Locations
Layout table for location information
Denmark
Zealand University Hospital
Roskilde, Denmark, 4000
Contact: Sebastian W Nielsen         
Sponsors and Collaborators
University of Copenhagen
Zealand University Hospital
Investigators
Layout table for investigator information
Study Chair: Jens Rikardt Andersen, MD University of Copenhagen
Principal Investigator: Sebastian W Nielsen, MD Zealand University Hospital
Layout table for additonal information
Responsible Party: Jens Rikardt Andersen, Associate professor, University of Copenhagen
ClinicalTrials.gov Identifier: NCT04585841    
Other Study ID Numbers: SJ-846
First Posted: October 14, 2020    Key Record Dates
Last Update Posted: October 22, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jens Rikardt Andersen, University of Copenhagen:
Cannabidiol
Cancer cachexia
Nausea
Emesis
Lean Body Mass
Oxaliplatin
Paclitaxel
Appetite
Adult
Quality of life
Taste alteration
Additional relevant MeSH terms:
Layout table for MeSH terms
Epidiolex
Wasting Syndrome
Nausea
Cachexia
Signs and Symptoms, Digestive
Emaciation
Weight Loss
Body Weight Changes
Body Weight
Metabolic Diseases
Nutrition Disorders
Anticonvulsants